Phase 2 trial of pegylated liposomal XXXX in advanced @entity1204 .

@entity632 @entity1 @entity1204 @entity137 @entity390 @entity417 @entity2700 @entity3003 @entity900 @entity1311 @entity391 @entity8566 @entity299
PURPOSE: To evaluate the efficacy and @entity137 of pegylated liposomal @entity632 in @entity1 with advanced @entity1204 . METHODS: Pegylated liposomal @entity632 was administered at a dose of 40 mg/m2, and repeated on an every 28-day schedule. RESULTS: A total of 19 @entity1 were enrolled in this phase 2 trial. Fourteen @entity1 had received prior chemotherapy ( @entity3003 / @entity1311 -9; @entity900 / @entity1311 -3; single agent @entity1311 -2), seven prior radiation therapy, and three prior hormonal therapy. No @entity1 had previously received @entity632 . Two @entity1 (11%) developed grade 1 @entity8566 following treatment with pegylated liposomal @entity632 . There were no episodes of @entity299 (>10% reduction in baseline ejection fraction). Three @entity1 required hospitalization for @entity390 , @entity391 , @entity417 , and @entity2700 . Only 2 (11%) @entity1 required dose reduction. Four of 19 @entity1 (21%; 95% CI: 3-39%) evaluable for response exhibited objective and subjective evidence of an antineoplastic effect of therapy (duration of responses: 2 months, 3 months, 4 months, 6+ months). CONCLUSION: The pegylated liposomal @entity632 regimen employed in this trial exhibited an acceptable @entity137 profile ( @entity299 , @entity8566 ). Definite, although modest, antineoplastic activity in a @entity1 population with recurrent or advanced @entity1204 was documented.
